Connect with us

Global Immunoassay Market Report 2022: FDA Grants Breakthrough Device to Multiplex Immunoassay

Global Immunoassay Market Report 2022: FDA Grants Breakthrough Device to Multiplex Immunoassay
PR Newswire
DUBLIN, Feb. 14, 2022

DUBLIN, Feb. 14, 2022 /PRNewswire/ — The “Immunoassay Market: Strategies and Trends, Forecasts by Application, Technol…

Published

on

Global Immunoassay Market Report 2022: FDA Grants Breakthrough Device to Multiplex Immunoassay

PR Newswire

DUBLIN, Feb. 14, 2022 /PRNewswire/ -- The "Immunoassay Market: Strategies and Trends, Forecasts by Application, Technology, Product, User and by Country, with Multiplex and Point of Care Market Analysis, Executive Guides, Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.

The workhorse of the diagnostic industry is finding new legs. The pandemic has created a new demand for rapid easily available diagnostics. Immunoassay is stepping up.

Advances in genetic knowledge are creating new markets for immunoassay. Rapid diagnostics, point of care, biomarkers and consumer markets are all areas of expansion while traditional immunoassay maintains a strong position in the growing market for clinical diagnostics.

The publisher profiles 58 companies, large and small, working in this area. This research makes you the expert in your organization.

Make investment decisions and valuations with confidence using the latest data. The report includes five year market forecasts.

Market Trends

Factors Driving Growth

  • Diagnostic Factors
  • Changing Technologies Spur Early Instrument Retirement
  • Consumer Channels Open Wider
  • Immunity Technology Comes of Age

Factors Limiting Growth

  • Increased Competition Lowers Price
  • Threat from PCR Based Instruments
  • Lower Barriers to Entry
  • Wellness has a downside

Immunoassay Instrumentation

  • Instrumentation Tenacity
  • Declining Cost of Instruments Changes Industry Structure
  • Listing of Instrument Specifications
  • Immunoassay - CRISPR Diagnostics

Immunoassay Recent Developments

  • FDA Grants EUA to Xtrava Health COVID Point-of-Care Antigen Test
  • Alamar Biosciences Raises $80M for Immuno-Sandwich Assay Platform
  • FDA grants breakthrough device to multiplex immunoassay
  • Quidel, Beckman Settle Cardiac Immunoassay Dispute
  • BGI Americas, Advaite Form SARS-CoV-2 Testing Partnership
  • BioMerieux Gets CE Mark for Three Dengue Immunoassays
  • COVID-19 Portfolio to Accelerate At-Home Infectious Disease Testing
  • Roche Diagnostics Expanding Testing Portfolio in 2021
  • PerkinElmer Long-Term Outlook
  • Quidel Updates Outlook for C19 Testing
  • Dx Companies Look at Multiplex Tests for SARS-CoV-2, Influenza
  • Becton Dickinson and NAT Diagnostics Acquisition
  • New test diagnoses Lyme disease within 15 minutes
  • Multiplexed Immunoassay System Differentiates Malaria Species
  • ERBA Mannheim Unveils Next-Generation Nexus unit
  • Uman Diagnostics And Bio-Techne Announce Agreement For Neurofilament Light Assay
  • Software reduces variability in ELISA biomarker tests
  • Arrayit Corporation Allergy Testing Network Doubles

Industry Overview

Industry Participants

  • IVD Supplier
  • Independent lab specialized/esoteric
  • Independent lab national/regional
  • Independent lab analytical
  • Public National/regional lab
  • Hospital lab
  • Physician lab
  • Audit body

The Clinical Laboratory Market Segments

  • Traditional Market Segmentation
  • Laboratory Focus and Segmentation
  • Hospital Testing Share
  • Economies of Scale
  • Hospital vs. Central Lab
  • Physician Office Lab's
  • Physician's and POCT

Immunoassay -Markets and Discussion

  • Instruments - Genetics changes the picture
  • RIA - A Technology Shows its Age
  • Immunoassay vs. PCR vs. Sequencing - A See-Saw Battle
  • The Smart Shrinking Instrument - Serious Implications
  • Research Funding and Capital Expense - Instrument Pooling
  • Multiplex vs. POC - A Tradeoff Analysis
  • Reagents and Kits - Genetics changes the picture
  • Bigger Test Menus a Boon for Kit Market
  • Physician Office Labs - A New Frontier
  • Rapid and POCT to Threaten Instrument Markets
  • OTC and DTC - Huge Market Potential
  • Economies of Scale. Going Away?
  • Lower Barriers to Entry for Instruments/Analyzers
  • Miniaturization and Technology Drive Acquisition

Profiles of Key Companies

  • Abbott Diagnostics
  • Abcam
  • Arlington Scientific
  • Arrayit Corporation
  • Autobio Diagnostics
  • Awareness Technology
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Biocartis
  • Biomatik
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • BioTek Instruments
  • Boditech Med, Inc
  • Boster Biological Technology
  • Diamedix (Erba Diagnostics)
  • Diasorin S.p.A.
  • Dynex Technologies
  • Enzo Biochem
  • Eurofins Scientific
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Gold Standard Diagnostics
  • Grifols
  • Hycor Biomedical
  • Immunodiagnostic Systems (IDS)
  • Immunodiagnostik AG
  • Inova Diagnostics
  • JR Biomedical
  • Luminex Corp
  • Maxim Biomedical
  • Mbio Diagnostics
  • Meso Scale Discovery
  • Millipore Sigma
  • Mindray
  • Molecular Devices
  • MP Biomedical
  • MyCartis
  • Operon
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Qiagen Gmbh
  • Quidel
  • R&D Systems
  • Randox Toxicology
  • Roche Molecular Diagnostics
  • SD Biosensor
  • Serametrix
  • Siemens Healthineers
  • Sysmex
  • Tecan
  • Thermo Fisher Scientific Inc.
  • TOSOH Bioscience
  • Veredus Laboratories
  • Vircell
  • YD Diagnostics

For more information about this report visit https://www.researchandmarkets.com/r/k6q6rb

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:https://www.prnewswire.com/news-releases/global-immunoassay-market-report-2022-fda-grants-breakthrough-device-to-multiplex-immunoassay-301481451.html

SOURCE Research and Markets

Read More

Continue Reading

Uncategorized

Homes listed for sale in early June sell for $7,700 more

New Zillow research suggests the spring home shopping season may see a second wave this summer if mortgage rates fall
The post Homes listed for sale in…

Published

on

  • A Zillow analysis of 2023 home sales finds homes listed in the first two weeks of June sold for 2.3% more. 
  • The best time to list a home for sale is a month later than it was in 2019, likely driven by mortgage rates.
  • The best time to list can be as early as the second half of February in San Francisco, and as late as the first half of July in New York and Philadelphia. 

Spring home sellers looking to maximize their sale price may want to wait it out and list their home for sale in the first half of June. A new Zillow® analysis of 2023 sales found that homes listed in the first two weeks of June sold for 2.3% more, a $7,700 boost on a typical U.S. home.  

The best time to list consistently had been early May in the years leading up to the pandemic. The shift to June suggests mortgage rates are strongly influencing demand on top of the usual seasonality that brings buyers to the market in the spring. This home-shopping season is poised to follow a similar pattern as that in 2023, with the potential for a second wave if the Federal Reserve lowers interest rates midyear or later. 

The 2.3% sale price premium registered last June followed the first spring in more than 15 years with mortgage rates over 6% on a 30-year fixed-rate loan. The high rates put home buyers on the back foot, and as rates continued upward through May, they were still reassessing and less likely to bid boldly. In June, however, rates pulled back a little from 6.79% to 6.67%, which likely presented an opportunity for determined buyers heading into summer. More buyers understood their market position and could afford to transact, boosting competition and sale prices.

The old logic was that sellers could earn a premium by listing in late spring, when search activity hit its peak. Now, with persistently low inventory, mortgage rate fluctuations make their own seasonality. First-time home buyers who are on the edge of qualifying for a home loan may dip in and out of the market, depending on what’s happening with rates. It is almost certain the Federal Reserve will push back any interest-rate cuts to mid-2024 at the earliest. If mortgage rates follow, that could bring another surge of buyers later this year.

Mortgage rates have been impacting affordability and sale prices since they began rising rapidly two years ago. In 2022, sellers nationwide saw the highest sale premium when they listed their home in late March, right before rates barreled past 5% and continued climbing. 

Zillow’s research finds the best time to list can vary widely by metropolitan area. In 2023, it was as early as the second half of February in San Francisco, and as late as the first half of July in New York. Thirty of the top 35 largest metro areas saw for-sale listings command the highest sale prices between May and early July last year. 

Zillow also found a wide range in the sale price premiums associated with homes listed during those peak periods. At the hottest time of the year in San Jose, homes sold for 5.5% more, a $88,000 boost on a typical home. Meanwhile, homes in San Antonio sold for 1.9% more during that same time period.  

 

Metropolitan Area Best Time to List Price Premium Dollar Boost
United States First half of June 2.3% $7,700
New York, NY First half of July 2.4% $15,500
Los Angeles, CA First half of May 4.1% $39,300
Chicago, IL First half of June 2.8% $8,800
Dallas, TX First half of June 2.5% $9,200
Houston, TX Second half of April 2.0% $6,200
Washington, DC Second half of June 2.2% $12,700
Philadelphia, PA First half of July 2.4% $8,200
Miami, FL First half of June 2.3% $12,900
Atlanta, GA Second half of June 2.3% $8,700
Boston, MA Second half of May 3.5% $23,600
Phoenix, AZ First half of June 3.2% $14,700
San Francisco, CA Second half of February 4.2% $50,300
Riverside, CA First half of May 2.7% $15,600
Detroit, MI First half of July 3.3% $7,900
Seattle, WA First half of June 4.3% $31,500
Minneapolis, MN Second half of May 3.7% $13,400
San Diego, CA Second half of April 3.1% $29,600
Tampa, FL Second half of June 2.1% $8,000
Denver, CO Second half of May 2.9% $16,900
Baltimore, MD First half of July 2.2% $8,200
St. Louis, MO First half of June 2.9% $7,000
Orlando, FL First half of June 2.2% $8,700
Charlotte, NC Second half of May 3.0% $11,000
San Antonio, TX First half of June 1.9% $5,400
Portland, OR Second half of April 2.6% $14,300
Sacramento, CA First half of June 3.2% $17,900
Pittsburgh, PA Second half of June 2.3% $4,700
Cincinnati, OH Second half of April 2.7% $7,500
Austin, TX Second half of May 2.8% $12,600
Las Vegas, NV First half of June 3.4% $14,600
Kansas City, MO Second half of May 2.5% $7,300
Columbus, OH Second half of June 3.3% $10,400
Indianapolis, IN First half of July 3.0% $8,100
Cleveland, OH First half of July  3.4% $7,400
San Jose, CA First half of June 5.5% $88,400

 

The post Homes listed for sale in early June sell for $7,700 more appeared first on Zillow Research.

Read More

Continue Reading

Government

Survey Shows Declining Concerns Among Americans About COVID-19

Survey Shows Declining Concerns Among Americans About COVID-19

A new survey reveals that only 20% of Americans view covid-19 as "a major threat"…

Published

on

Survey Shows Declining Concerns Among Americans About COVID-19

A new survey reveals that only 20% of Americans view covid-19 as "a major threat" to the health of the US population - a sharp decline from a high of 67% in July 2020.

(SARMDY/Shutterstock)

What's more, the Pew Research Center survey conducted from Feb. 7 to Feb. 11 showed that just 10% of Americans are concerned that they will  catch the disease and require hospitalization.

"This data represents a low ebb of public concern about the virus that reached its height in the summer and fall of 2020, when as many as two-thirds of Americans viewed COVID-19 as a major threat to public health," reads the report, which was published March 7.

According to the survey, half of the participants understand the significance of researchers and healthcare providers in understanding and treating long COVID - however 27% of participants consider this issue less important, while 22% of Americans are unaware of long COVID.

What's more, while Democrats were far more worried than Republicans in the past, that gap has narrowed significantly.

"In the pandemic’s first year, Democrats were routinely about 40 points more likely than Republicans to view the coronavirus as a major threat to the health of the U.S. population. This gap has waned as overall levels of concern have fallen," reads the report.

More via the Epoch Times;

The survey found that three in ten Democrats under 50 have received an updated COVID-19 vaccine, compared with 66 percent of Democrats ages 65 and older.

Moreover, 66 percent of Democrats ages 65 and older have received the updated COVID-19 vaccine, while only 24 percent of Republicans ages 65 and older have done so.

“This 42-point partisan gap is much wider now than at other points since the start of the outbreak. For instance, in August 2021, 93 percent of older Democrats and 78 percent of older Republicans said they had received all the shots needed to be fully vaccinated (a 15-point gap),” it noted.

COVID-19 No Longer an Emergency

The U.S. Centers for Disease Control and Prevention (CDC) recently issued its updated recommendations for the virus, which no longer require people to stay home for five days after testing positive for COVID-19.

The updated guidance recommends that people who contracted a respiratory virus stay home, and they can resume normal activities when their symptoms improve overall and their fever subsides for 24 hours without medication.

“We still must use the commonsense solutions we know work to protect ourselves and others from serious illness from respiratory viruses, this includes vaccination, treatment, and staying home when we get sick,” CDC director Dr. Mandy Cohen said in a statement.

The CDC said that while the virus remains a threat, it is now less likely to cause severe illness because of widespread immunity and improved tools to prevent and treat the disease.

Importantly, states and countries that have already adjusted recommended isolation times have not seen increased hospitalizations or deaths related to COVID-19,” it stated.

The federal government suspended its free at-home COVID-19 test program on March 8, according to a website set up by the government, following a decrease in COVID-19-related hospitalizations.

According to the CDC, hospitalization rates for COVID-19 and influenza diseases remain “elevated” but are decreasing in some parts of the United States.

Tyler Durden Sun, 03/10/2024 - 22:45

Read More

Continue Reading

Government

Rand Paul Teases Senate GOP Leader Run – Musk Says “I Would Support”

Rand Paul Teases Senate GOP Leader Run – Musk Says "I Would Support"

Republican Kentucky Senator Rand Paul on Friday hinted that he may jump…

Published

on

Rand Paul Teases Senate GOP Leader Run - Musk Says "I Would Support"

Republican Kentucky Senator Rand Paul on Friday hinted that he may jump into the race to become the next Senate GOP leader, and Elon Musk was quick to support the idea. Republicans must find a successor for periodically malfunctioning Mitch McConnell, who recently announced he'll step down in November, though intending to keep his Senate seat until his term ends in January 2027, when he'd be within weeks of turning 86. 

So far, the announced field consists of two quintessential establishment types: John Cornyn of Texas and John Thune of South Dakota. While John Barrasso's name had been thrown around as one of "The Three Johns" considered top contenders, the Wyoming senator on Tuesday said he'll instead seek the number two slot as party whip. 

Paul used X to tease his potential bid for the position which -- if the GOP takes back the upper chamber in November -- could graduate from Minority Leader to Majority Leader. He started by telling his 5.1 million followers he'd had lots of people asking him about his interest in running...

...then followed up with a poll in which he predictably annihilated Cornyn and Thune, taking a 96% share as of Friday night, with the other two below 2% each. 

Elon Musk was quick to back the idea of Paul as GOP leader, while daring Cornyn and Thune to follow Paul's lead by throwing their names out for consideration by the Twitter-verse X-verse. 

Paul has been a stalwart opponent of security-state mass surveillance, foreign interventionism -- to include shoveling billions of dollars into the proxy war in Ukraine -- and out-of-control spending in general. He demonstrated the latter passion on the Senate floor this week as he ridiculed the latest kick-the-can spending package:   

In February, Paul used Senate rules to force his colleagues into a grueling Super Bowl weekend of votes, as he worked to derail a $95 billion foreign aid bill. "I think we should stay here as long as it takes,” said Paul. “If it takes a week or a month, I’ll force them to stay here to discuss why they think the border of Ukraine is more important than the US border.”

Don't expect a Majority Leader Paul to ditch the filibuster -- he's been a hardy user of the legislative delay tactic. In 2013, he spoke for 13 hours to fight the nomination of John Brennan as CIA director. In 2015, he orated for 10-and-a-half-hours to oppose extension of the Patriot Act

Rand Paul amid his 10 1/2 hour filibuster in 2015

Among the general public, Paul is probably best known as Capitol Hill's chief tormentor of Dr. Anthony Fauci, who was director of the National Institute of Allergy and Infectious Disease during the Covid-19 pandemic. Paul says the evidence indicates the virus emerged from China's Wuhan Institute of Virology. He's accused Fauci and other members of the US government public health apparatus of evading questions about their funding of the Chinese lab's "gain of function" research, which takes natural viruses and morphs them into something more dangerous. Paul has pointedly said that Fauci committed perjury in congressional hearings and that he belongs in jail "without question."   

Musk is neither the only nor the first noteworthy figure to back Paul for party leader. Just hours after McConnell announced his upcoming step-down from leadership, independent 2024 presidential candidate Robert F. Kennedy, Jr voiced his support: 

In a testament to the extent to which the establishment recoils at the libertarian-minded Paul, mainstream media outlets -- which have been quick to report on other developments in the majority leader race -- pretended not to notice that Paul had signaled his interest in the job. More than 24 hours after Paul's test-the-waters tweet-fest began, not a single major outlet had brought it to the attention of their audience. 

That may be his strongest endorsement yet. 

Tyler Durden Sun, 03/10/2024 - 20:25

Read More

Continue Reading

Trending